News | Radiation Therapy | April 26, 2017

Nine New Disease Sites Added to the NCCN Radiation Therapy Compendium

Compendium provides a single access point for radiation therapy recommendations within 33 NCCN Guidelines

Nine New Disease Sites Added to the NCCN Radiation Therapy Compendium

April 26, 2017 — The National Comprehensive Cancer Network (NCCN) continues to build its NCCN Radiation Therapy Compendium with the publication of radiation therapy (RT) recommendations from an additional nine NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines):

The new guidelines include recommendations for:

  • Acute Lymphoblastic Leukemia, Version 2.2016;
  • Basal Cell Skin Cancer, Version 1.2017;
  • Dermatofibrosarcoma Protuberans, Version 1.2017;
  • Gastric Cancer, Version 1.2017;
  • Hodgkin Lymphoma, Version 1.2017;
  • Merkel Cell Carcinoma, Version 1.2017;
  • Ovarian Cancer, Version 1.2017;
  • Squamous Cell Skin Cancer, Version 1.2017; and
  • Thymomas and Thymic Carcinomas, Version 1.2017.

Launched in March 2017, the NCCN Radiation Therapy Compendium now includes recommendations from 33 NCCN Guidelines. Additional cancer types will be published on a rolling basis over the coming months.

The compendium provides guidance on all RT modalities recommended within the NCCN Guidelines, including:

  • Intensity modulated radiation therapy (IMRT);
  • Intra-operative radiation therapy (IORT);
  • Stereotactic radiosurgery (SRS)/stereotactic body radiotherapy (SBRT)/stereotactic ablative radiotherapy (SABR);
  • Image-guided radiotherapy (IGRT);
  • Low dose-rate brachytherapy (LDR)/High dose-rate brachytherapy (HDR);
  • Radioisotope; and
  • Particle therapy.

Transparency of NCCN Guidelines and Compendia development is central to the philosophy, policies and procedures of NCCN. NCCN posts the policies and processes for developing and maintaining the NCCN Guidelines. These policies are available to the public on the NCCN website. Identification of newly published research, NCCN Member Institution review, external stakeholder submissions and panel review occur on an ongoing basis with at least annual review performed for NCCN Guidelines for each disease.

For more information: www.nccn.org

Related Content

Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
150-Year-Old Drug Might Improve Radiation Therapy for Cancer
News | Radiation Therapy | November 02, 2018
November 2, 2018 — A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more